QRX009

Topical Rapamycin Formulation for Rare Vascular and Skin Malformations

QRX009 is a proprietary topical formulation of rapamycin (sirolimus) in development as a potential treatment for a group of rare, disfiguring conditions, including Microcystic Lymphatic Malformations (MLM), Venous Malformations (VM), and Cutaneous Angiofibromas. These diseases can lead to significant cosmetic and functional impairment, and there are currently either none or limited FDA-approved topical therapies for these indications.

QRX009 is designed to optimize local skin penetration and deliver rapamycin directly to the affected dermal layers where it can be most effective. Previous clinical observations strongly suggest that limited drug delivery has contributed to underperformance of other topical rapamycin products. QRX009 is intended to address this challenge by optimizing the retention and absorption of the rapamycin directly at the target site.

Quoin plans to submit Investigational New Drug (IND) applications for at least two of these indications in 2025, with clinical development expected to commence in 1H 2026.